RECRUITING

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) are long-term autoimmune diseases in which the immune system attacks parts of the body. The abnormal immune reaction causes inflammation of and damage to various body parts and can affect joints, skin, kidneys, heart, lungs, blood vessels, and the brain. SLE and MCTD often affect young women, especially black and Hispanic women, and there is no known cure. Knowing more about SLE and MCTD will help in developing new and effective treatments. The purpose of this study is to characterize immune system abnormalities, genetic components, and disease progression in people with SLE and MCTD.

Official Title

Immune Response to Small Nuclear Ribonucleoprotein Autoantigens

Quick Facts

Study Start:2007-10
Study Completion:2029-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00582881

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 100 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with known rheumatic diseases including systemic lupus erythematosus, rheumatoid arthritis, connective tissue disease, undifferentiated connective tissue disease
  1. * Poor venous access, unstable medical problems or significant cardiopulmonary disease, anemia, leukopenia, thrombocytopenia, anticoagulation therapy, recent significant changes in medication or pregnacy. Patient cannot be taking large dose of corticosteroids (above 30mg per day) or cytotoxic drugs (cyclophosphamide, azathiprine, cyclosporine, methotrexate).

Contacts and Locations

Study Contact

Bethly Aubourg, MD
CONTACT
305-243-8567
baubourg@med.miami.edu
Eric L. Greidinger, MD
CONTACT
305-243-8913
egreidinger@med.miami.edu

Principal Investigator

Eric L. Greidinger, MD
PRINCIPAL_INVESTIGATOR
University of Miami

Study Locations (Sites)

University of Miami Miller School of Medicine
Miami, Florida, 33136
United States

Collaborators and Investigators

Sponsor: University of Miami

  • Eric L. Greidinger, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2007-10
Study Completion Date2029-09

Study Record Updates

Study Start Date2007-10
Study Completion Date2029-09

Terms related to this study

Keywords Provided by Researchers

  • Anti-RNP/Sm Autoantibody-Positive
  • MCTD
  • SLE

Additional Relevant MeSH Terms

  • Mixed Connective Tissue Disease (MCTD)
  • Systemic Lupus Erythematosus (SLE)